Reviewer's report

Title: CD1a expression in psoriatic skin following treatment with propylthiouracil, an antithyroid thioureylene

Authors:
Dr Alan N Elias (anelias@uci.edu)
Vandana S Nanda (vsnanda@uci.edu)
Ronald J Barr (ribarr@uci.edu)

Version: 1 Date: 5 Jun 2003

Reviewer: Fahrettin Kelestimur

Level of interest: A paper whose findings are important to those with closely related research interests

Advice on publication: Accept after discretionary revisions

1) Comments
a) Discretionary revisions:
1. Page 5, paragraph 3, line 3: Since PTU is a potentially hepatotoxic drug, it would be better to add serum transaminases (if obtained)
2. Page 8, Discussion, 7th line from bottom: To draw a conclusion that "the inability of PTU to reduce CD1a expression implies that the effect of this drug is not due to the production of IL-12" is assertive without establishing IL-12 levels. It would be better to add the circulating IL-12 levels (which is already submitted) to this paper.
3. Page 4, 3rd paragraph, line 4: ".......patients with known hypothyroidism.....". It would be better to change as "patients with thyroid dysfunction" in order to emphasize both, hypo and hyperthyroidism.

Competing interests:
None declared.